Quick Takeaways:
- ECO Animal Health has received a favourable safety assessment from the USDA for Ecovaxxin MG, a live vaccine targeting Mycoplasma gallisepticum. The decision marks a key step toward US marketing authorisation, with final regulatory submission expected in late 2027
- The USDA review confirmed the vaccine’s safety across both target (chickens) and non-target species (turkeys and quails), while also demonstrating stability with no reversion to virulence after passage. The vaccine uses a naturally attenuated bacterial strain designed to protect against respiratory disease in poultry
- This milestone builds on ECO’s broader vaccine strategy, following progress with its Ecovaxxin MS candidate, expected to launch in 2026. With a growing R&D pipeline, the company is advancing innovative solutions to address Mycoplasma infections and strengthen its position in the global poultry vaccine market
Why It Matters?
The USDA’s positive safety verdict for Ecovaxxin MG significantly de‑risks US registration, validating ECO’s live‑strain platform and setting up a clear path toward a 2027 filing in a large Mycoplasma gallisepticum market.
Combined with the upcoming Ecovaxxin MS launch, the decision strengthens ECO’s strategic pivot toward proprietary poultry vaccines, positioning the company as a differentiated Mycoplasma specialist rather than just a generic anti‑infectives player.
Source: ECO Animal Health
